Last $15.24 USD
Change Today +0.53 / 3.60%
Volume 610.6K
INFI On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 11/26/14 All times are local (Market data is delayed by at least 15 minutes).

infinity pharmaceuticals inc (INFI) Snapshot

Open
$14.75
Previous Close
$14.71
Day High
$15.35
Day Low
$14.73
52 Week High
12/9/13 - $18.35
52 Week Low
05/7/14 - $8.40
Market Cap
743.2M
Average Volume 10 Days
594.1K
EPS TTM
$-0.25
Shares Outstanding
48.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INFINITY PHARMACEUTICALS INC (INFI)

infinity pharmaceuticals inc (INFI) Related Businessweek News

No Related Businessweek News Found

infinity pharmaceuticals inc (INFI) Details

Infinity Pharmaceuticals, Inc., a drug discovery and development company, focuses on discovering, developing, and delivering medicines to people with difficult-to-treat diseases. Its lead product candidate includes IPI-145, an oral inhibitor of Class I delta and gamma isoforms of phosphoinositide-3-kinase (PI3K) for the treatment of hematologic malignancies and inflammatory diseases. The company is conducting DUOTM, a randomized, monotherapy Phase 3 study of IPI-145 in patients with relapsed/refractory chronic lymphocytic leukemia; an ongoing Phase 1 dose-escalation study to evaluate the safety, pharmacokinetics, and clinical activity of IPI-145 in patients with advanced hematologic malignancies; a Phase 2 study to evaluate the efficacy, safety, and pharmacokinetics of IPI-145 in patients with rheumatoid arthritis; and a Phase 2a trial of IPI-145 in patients with mild allergic asthma, as well as completed a Phase 1 trial of IPI-145 in healthy adult subjects. It also develops IPI-443, an oral inhibitor of PI3K-delta and gamma; and IPI-940, an inhibitor of fatty acid amide hydrolase. The company has strategic collaboration with AbbVie Inc. to develop and commercialize duvelisib (IPI-145) in oncology. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

180 Employees
Last Reported Date: 02/25/14

infinity pharmaceuticals inc (INFI) Top Compensated Officers

Chairman of The Board, Chief Executive Office...
Total Annual Compensation: $552.0K
Chief Financial Officer, Chief Business Offic...
Total Annual Compensation: $378.8K
President of Research & Development
Total Annual Compensation: $465.8K
Chief Scientific Officer
Total Annual Compensation: $366.4K
Compensation as of Fiscal Year 2013.

infinity pharmaceuticals inc (INFI) Key Developments

Infinity Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for Third Quarter and Nine Months Ended September 30, 2014; Revises Earnings Guidance for the Full Year of 2014

Infinity Pharmaceuticals, Inc. announced unaudited consolidated earnings results for third quarter and nine months ended September 30, 2014. For the quarter, the company reported collaboration revenue of $160,639,000. Income from operations of $107,702,000 against loss from operations of $34,176,000 for the same quarter a year ago. Net income was $103,217,000 or $2.03 per diluted share against net loss of $33,938,000 or $0.71 per basic and diluted share, for the same quarter a year ago. For the nine months period, the company reported collaboration revenue of $160,639,000. Income from operations of $31,185,000 against loss from operations of $94,592,000 for the same period a year ago. Net income was $22,926,000 or $0.46 per diluted share against net loss of $93,855,000 or $1.96 per basic and diluted share, for the same period a year ago. The company revised its earnings guidance for the full year of 2014. The company expects revenue for 2014 to range from $160 million to $170 million. Previously, the company did not expect to recognize any revenue in 2014. The company expects net loss for 2014 to range from $20 million to $30 million, compared to prior expectations of $170 million to $180 million. The company expects to end 2014 with a year-end cash and investments balance ranging from $320 million to $330 million, compared to prior expectations of $40 million to $50 million.

Infinity Pharmaceuticals, Inc. Presents at Goldman Sachs Group 2014 US Emerging / SMID Cap Growth Conference, Nov-20-2014 11:30 AM

Infinity Pharmaceuticals, Inc. Presents at Goldman Sachs Group 2014 US Emerging / SMID Cap Growth Conference, Nov-20-2014 11:30 AM. Venue: New York Marriott Marquis, New York, New York, United States.

Infinity Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 01:50 PM

Infinity Pharmaceuticals, Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 01:50 PM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Adelene Q. Perkins, Chairman of the Board, Chief Executive Officer and President, Kate Murray, Senior Investor Relations Associate.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INFI:US $15.24 USD +0.53

INFI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Array BioPharma Inc $3.95 USD +0.03
CTI BioPharma Corp $2.23 USD -0.01
Evotec AG €3.27 EUR +0.04
Exelixis Inc $1.76 USD +0.04
GlaxoSmithKline SAE £12.94 EGP 0.00
View Industry Companies
 

Industry Analysis

INFI

Industry Average

Valuation INFI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 4.5x
Price/Book 2.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INFINITY PHARMACEUTICALS INC, please visit www.infi.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.